Clinical Trial

Clinical Study on the Efficacy and Safety of Nalfurafine Hydrochloride Orally Disintegrating Tablets in Treating Pruritus in Patients Undergoing Maintenance Hemodialysis

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This is a randomized, open-label, multi-center clinical study aimed at evaluating the efficacy and safety of 12 weeks of nalfurafine hydrochloride administration in the treatment of pruritus in patients undergoing maintenance hemodialysis.
Trial Details
NCT Number NCT07650851
Lead Sponsor Chinese PLA General Hospital
Collaborators: The First Affiliated Hospital of Dalian Medical University, Beijing Friendship Hospital, The General Hospital of Northern Theater Command, Tianjin First Central Hospital, RenJi Hospital, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Xiangyang Central Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Jiangsu Taizhou People's Hospital, Qilu Hospital of Shandong University, First Affiliated Hospital Xi'an Jiaotong University, Zigong No.1 Peoples Hospital, Chengdu First People's Hospital, The People's Hospital of Leshan, The Third Affiliated Hospital of Wenzhou Medical University, Henan Provincial People's Hospital, Shanghai Changzheng Hospital, Daping Hospital of Army Medical University, First Affiliated Hospital of Wannan Medical College
Conditions Chronic Kidney Disease-Associated Pruritus in Hemodialysis
Enrollment 150 participants
Start Date 2026-07-01
Primary Completion 2028-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-16